GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (STU:VT6) » Definitions » Total Assets

Voyager Therapeutics (STU:VT6) Total Assets : €432.0 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Voyager Therapeutics Total Assets?

Voyager Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was €432.0 Mil.

During the past 12 months, Voyager Therapeutics's average Total Assets Growth Rate was 11.20% per year. During the past 3 years, the average Total Assets Growth Rate was 14.40% per year. During the past 5 years, the average Total Assets Growth Rate was 20.90% per year. During the past 10 years, the average Total Assets Growth Rate was 73.60% per year.

During the past 11 years, Voyager Therapeutics's highest 3-Year average Total Assets Growth Rate was 926.60%. The lowest was -17.90%. And the median was 46.80%.

Total Assets is connected with ROA %. Voyager Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -11.06%. Total Assets is also linked to Revenue through Asset Turnover. Voyager Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.05.


Voyager Therapeutics Total Assets Historical Data

The historical data trend for Voyager Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics Total Assets Chart

Voyager Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 319.28 215.02 171.56 150.43 322.13

Voyager Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 314.10 291.24 276.09 322.13 432.03

Voyager Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Voyager Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=216.705+105.419
=322.1

Voyager Therapeutics's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=313.615+118.41
=432.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Voyager Therapeutics  (STU:VT6) Total Assets Explanation

Total Assets is connected with ROA %.

Voyager Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-41.696/( (322.125+432.025)/ 2 )
=-41.696/377.075
=-11.06 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Voyager Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=17.955/( (322.125+432.025)/ 2 )
=17.955/377.075
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Voyager Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyager Therapeutics (STU:VT6) Business Description

Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Voyager Therapeutics (STU:VT6) Headlines

No Headlines